Dublin, Dec. 23, 2016 -- Research and Markets has announced the addition of the "Type 2 Diabetes Drugs Price Analysis and Strategies - 2016" report to their offering.
Type 2 Diabetes Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Type 2 Diabetes market.
The research answers the following questions:
- What are the key drugs marketed for Type 2 Diabetes and their clinical attributes? How are they positioned in the Global Type 2 Diabetes market?
- What are the unit prices and annual treatment cost for Type 2 Diabetes therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Type 2 Diabetes drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Type 2 Diabetes?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Type 2 Diabetes including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Type 2 Diabetes
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Type 2 Diabetes market
- Type 2 Diabetes Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Type 2 Diabetes New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/gnpmx2/type_2_diabetes
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorder Drugs


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 



